GOSS

Gossamer is a clinical-stage, single-product company whose entire value rests on one molecule, seralutinib, and one event: the PROSERA Phase 3 readout. The 10-K is explicit that the company 'depend[s] heavily on the ability to advance seralutinib through clinical development successfully' and warns that PROSERA 'may not be sufficient to support FDA approval.' There is no approved product, no recurring commercial revenue, and a workforce reduction already underway. The FY2025 'revenue' of $48.5M (down 57.7%) is not product sales — it is recognition of the Chiesi collaboration upfront and cost-sharing, so the 0.8x P/S is meaningless. The real engine is a $170M net loss and a $171M operating cash outflow.

The balance sheet is the disqualifier. Stockholders' equity is negative $123M, total liabilities are $295M against $172M of assets, and liabilities/equity of -2.40x reflects technical insolvency on a book basis. Management discloses $136.9M of cash, equivalents and marketable securities at year-end 2025 — but that sits against $200M of 5.00% 2027 Convertible Notes coming due, and the company concedes it 'may also use cash on hand to repurchase 2027 Notes.' At a $171M annual burn, the current cash does not fund the company through both a Phase 3 program and a near-term note maturity. The January 2026 shelf registration signals that more equity is coming, and at a $0.16 share price any raise is brutally dilutive to the 235M shares already outstanding.